Drug Trial Radar · NCT00211276
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Mar 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 2005
Primary completion
Jan 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to find out if the study drug, ONTAK (denileukin diftitox), can shrink or slow the growth of B-cell non-Hodgkin's lymphoma (NHL) in patients whose disease has not responded to prior treatments, or has relapsed after an initial response to prior treatments. The safety of treatment with ONTAK will also be studied. The hypothesis is that patients with relapsed or refractory B-cell NHL and mild to moderate myelosuppression treated with ONTAK at a new dosing regimen will respond sufficiently to warrant further study.
Conditions
- Lymphoma, B-Cell
Interventions
ONTAK (denileukin diftitox)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Response will be evaluated by CT or MRI scans at baseline, every 8 weeks while on therapy, and every 3 months after therapy, using standard response criteria defined by Cheson et al.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Tower Cancer Research Foundation
Beverly Hills, California
Pacific Coast Hematology/Oncology
Fountain Valley, California
University of California, Los Angeles
Los Angeles, California
Emory University
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Siouxland Hematology-Oncology
Sioux City, Iowa
Washington University Siteman Cancer Center
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
St. Vincent's Comprehensive Cancer Center
New York, New York
Case Comprehensive Cancer Center
Cleveland, Ohio
The Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.